Individualized Antithrombotic Risk Assessment & Therapy
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".
Deadline for manuscript submissions: closed (20 April 2023) | Viewed by 4830
Special Issue Editors
2. Diagnostic Services, Northern Health, Epping, Australia
3. Australian Centre for Blood Diseases, Monash University, Prahran, Melbourne, Australia
4. Department of Medicine, Northern Health, University of Melbourne, Epping, Australia
Interests: thrombosis; anticoagulation; venous thromboembolism; pulmonary embolism; hematology
Special Issues, Collections and Topics in MDPI journals
Interests: hematological indices in different diseases: environmental, inflammatory and genetic influences
Special Issue Information
Dear Colleagues,
One of the key challenges in the management of thrombotic and cardiovascular diseases is the need to carefully balance bleeding and thrombotic risk. This equilibrium is physiologically maintained by the careful counter-balancing of procoagulant and anticoagulant proteins and is in close relation with the endothelium and vessel flow. This homeostasis can be influenced by numerous risk factors and disrupted by a variety of pathophysiological events, resulting in thrombotic and cardiovascular diseases as well as bleeding. Anticoagulation as well as antiplatelet agents are some of the critical management strategies used in the attempt to restore the equilibrium. The management of anticoagulation and antiplatelet therapies in these conditions requires the careful identification of high-risk individuals and the individualisation of therapy to optimise anti-thrombotic effects while minimising bleeding complications. While the introduction of direct oral anticoagulants has improved both thrombotic and bleeding outcomes, further optimisation at the level of the individual is still required. The aim of this Special Issue is to explore the safety of current therapies as well as the ability of clinical risk assessment models and available diagnostic markers to effectuate an individualised approach for the prevention and treatment of thrombotic and cardiovascular diseases.
We invite original research articles and reviews on topics that may include but are not limited to:
- Clinical risk assessment models in thrombotic and cardiovascular diseases.
- Novel biomarkers, including global coagulation assays, proteomic markers, and other coagulation and/or endothelial biomarkers.
- The management of anticoagulation and/or antiplatelet therapies, including monitoring and dose adjustment.
- The management of rare thrombotic disorders, including cerebral venous thrombosis and splanchnic vein thrombosis.
- The management of anticoagulation in:
- Cancer patients;
- Obese patients;
- Antiphospholipid syndrome;
- Venous thrombosis with clinical equipoise for long-term anticoagulation;
- Peripheral vascular diseases, cerebral artery diseases, and/or coronary artery diseases.
Dr. Prahlad Ho
Dr. Amir Houshang Shemirani
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticoagulation
- thrombosis
- cardiovascular and peripheral vascular disease
- coagulation biomarkers
- thrombotic risk assessment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.